Sonoma Pharmaceuticals
SNOA
22 hedge funds and large institutions have $870K invested in Sonoma Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
22% more funds holding
Funds holding: 18 → 22 (+4)
5% more capital invested
Capital invested by funds: $825K → $870K (+$45K)
0.05% less ownership
Funds ownership: 0.1% → 0.04% (-0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$68.8K |
| 2 |
VF
Virtu Financial
New York
|
+$60.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$37.8K |
| 4 |
Goldman Sachs
New York
|
+$20K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$331K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$58K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.02K |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$3K |
| 5 |
BA
Bard Associates
Chicago,
Illinois
|
-$2.72K |
SNOA Hedge Fund Activity: Q1 2019 in Review
22 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q1 2019, worth a combined $870K — up 5.5% from $825K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SNOA positions and 4 closed out — a net gain of 4 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $68.8K. The largest seller was Sabby Management, exiting entirely with an estimated $331K sold.
- 22 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q1 2019, up from 18 in Q4 2018.
- Funds reported $870K of Sonoma Pharmaceuticals stock for Q1 2019, up 5.5% quarter-over-quarter.
- 8 funds opened new Sonoma Pharmaceuticals positions in Q1 2019 and 4 closed out, a net change of +4 holders.
- The largest Sonoma Pharmaceuticals buyer in Q1 2019 was Renaissance Technologies, an estimated $68.8K added.
- The largest Sonoma Pharmaceuticals seller in Q1 2019 was Sabby Management, an estimated $331K sold.
Based on aggregated 13F filings for Q1 2019.